Business
Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at AsiaTIDES Conference in Tokyo
Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at AsiaTIDES Conference in Tokyo.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at AsiaTIDES Conference in TokyoCompany also presents data on liposomal facilitation of cell-to-cell transfer of nucleic acidsBOTHELL, Wash., February 29, 2012 – Marina Biotech, Inc. (OTCQX:MRNA), a leading nucleic acid-based drug discovery and development company, today reported data demonstrating the continued advancement of the Company’s clinical program for CEQ508, the only orally administered RNAi therapeutic in clinical development. Data were also presented on early research in the oral administration of single and double-stranded nucleic acids. The data were presented by Michael V. Templin, Ph.D., Senior Vice President and Chief Technology Officer at Marina Biotech, Inc., and entitled “Advances in the Development of Orally Administered Nucleic Acid-based Therapeutics,” at AsiaTIDES, Oligonucleotide and Peptide(R) Research, Technology and Product Development, February 28 – March 1, 2012 in Tokyo, Japan.“We continue to advance our clinical development program, and we believe that CEQ508 will not only be the first orally delivered nucleic acid in the market but potentially the first RNAi drug to market,” stated Richard T. Ho, MD, Executive Vice President Research and Development. “The current drug product can be stored for extended time periods in home freezers or refrigerators allowing us the option of bringing a liquid formulation to market and thus minimizing the clinical development cycle. CEQ508 represents the first generation of tkRNAi™, and we are now focused on the development of second generation technology which is expected to provide us a platform for cell specific targeting throughout the entire gastrointestinal tract to treat both inflammatory and oncology diseases. In addition to the tkRNAi system, we are developing alternative methods to oligonucleotide therapeutic delivery via oral administration which dramatically improve both systemic exposure and bioavailability in a variety of tissue systems. Oral administration of oligonucleotide therapeutics as well as new efforts in harnessing cell-to-cell transfer of nucleic acids will be active areas for our research and development team in the immediate future.”About Marina Biotech, Inc.Marina Biotech is a biotechnology com...